Daniel Vasella news from FiercePharma
News
Vasella touts Novartis' diversification
Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, Read more...
What did Vasella see in Alcon?
Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...
SPOTLIGHT: Novartis: No more deals, no Roche sale
Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for Read more...
Novartis pledges $39B for Alcon
In a bid to diversify its business away from traditional pharma, Novartis has bought a 25 percent stake in Alcon and is eyeing the purchase of another 52 percent in 2010. The Swiss drugmaker paid Read more...
SPOTLIGHT: Vasella defends dual role at Novartis
Novartis Chairman and CEO Daniel Vasella (photo) got a bit defensive at his company's annual meeting yesterday. Questioned Read more...
Novartis CEO's statin? Pfizer's Lipitor
What's a pharma CEO with high cholesterol to do? Take his company's statin, of course. But Novartis chief Daniel Vasella (Read more...
CEO: Novartis plans big restructuring
On second thought, let's restructure the whole company: In October, Novartis announced some job cuts and management changes. Now, Read more...
Wyeth CEO: FDA creating monopoly meds
U.S. drug regulators aren't playing fair, says outgoing Wyeth CEO Bob Essner. New meds that should be allowed on the market--because they're safe and effective--are Read more...
FDA rejects embattled Novartis drug
Is expected bad news better than unexpected bad? Ask Novartis. Today the company announced the FDA's rejection of the Cox-2 painkiller Prexige--a thumbs-down that Read more...
Get more Daniel Vasella coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight